The study included 303 patients (110 men, 193 women) with Stage I-III arterial hypertension (AH), aged 25–70 years (mean age 52±18 years). All participants were divided into two groups, comparable by age and sex distribution: Group A (n=151) – with metabolic syndrome (MS), and Group B (n=152) – without MS. Each group was divided into three subgroups, according to AH stage (I, II, III). All patients underwent clinical examination, 24-hout blood pressure (BP) monitoring, renal function assessment (glomerular filtration rate, GFR, and microalbuminuria, MAU). MS criteria were specified according to the recommendations by International Diabetic Foundation (IDF, 2005). The data obtained demonstrated that MAU was an early marker of renal pathology in AH, especially when combined with MS. MAU level was significantly higher in individuals with AH and MS, comparing to hypertensive participants without metabolic disturbances. Group A demonstrated significant correlations between MAU, lipid and carbohydrate metabolism parameters and circadian BP profile. GFR correlation with MS was substantially weaker.

Left ventricular (LV) remodelling types were investigated in regard to their link to cardiac arrhythmias in patients with Type 2 diabetes mellitus (DM-2) and arterial hypertension (AH) or essential AH (EAH). Hypertrophic LV remodelling types (concentric and eccentric hypertrophy) were more common in individuals with DM-2 and AH or EAH, predicting high-grade ventricular extrasystoles and supraventricular arrhythmias (including paroxysmal atrial fibrillation).

High levels of medico-social therapy compliance were observed in coronary heart disease patients with adaptive psychoemotional reactivity types. Decreased compliance was associated with psycho- emotional disadaptation, typical for patients with pain type of myocardial ischemia.

In 108 patients, clinico-psychopathological features of anxiety disorders were studied before and after cardiac pacemaker (CPM) implantation, using the Hospital Anxiety and Depression Scale (HADS). Both at baseline and after CPM implantation, anxiety-phobic and general anxiety disorder were the most common features. In patients with CPM, prevalence and severity of anxiety disorders correlated with electrocaridostimulation (ECS) regime and duration, cardiac arrhythmia severity and ECS complications. These factors point to the need for psychological rehabilitation in CPM individuals

Six-month indapamide therapy was highly effective in 70 % of elderly patients with Stage I-II arterial hypertension (AH). In 30 %, a combination of indapamide with lisinopril was necessary for achieving target blood pressure (BP) levels. Indapamide therapy was associated with significant reduction in systolic and pulse BP, SBP variability, as well as with normalisation in circadian profile and morning dynamics of SBP and DBP. Twenty-four-week indapamide treatment resulted in significant reductions in left ventricular hypertrophy and aortal stiffness index, combined with nephroprotective effects. Indapamide did not affect carbohydrate, purine, and electrolyte metabolism. In elderly patients with AH, six-month indapamide therapy was linked to significant improvement in quality of life and cognitive and mnestic functioning

The study was aimed at investigating cell hemostasis parameters in acute coronary syndrome (ACS), and comparing the effects of various antiaggregant medications (clopidogrel, aspirin, or their combination) on platelet (PL) and red blood cell (RBC) aggregation activity. In total, 98 ACS patients were divided into groups, according to the antiaggregant therapy received. At Days 3-4 and 6-7, PL aggregation activity and RBC morphology and function were assessed. Antiaggregant therapy was highly effective among those receiving combined treatment, with minimal PL aggregation and maximal RBC morphology improvement (high prevalence of discocytes and reversibly deformed RBC) observed as early as Day 3 and further increasing by Day 7. All three variants of antiaggregant therapy were significantly effective, but Clopidogrel, especially in combination with aspirin, demonstrated the best effect. Combined therapy (clopidogrel and aspirin) improved cell hemostasis parameters, which could be linked to better aggregation inhibition due to different therapeutic targets for these two agents.